Show simple item record

dc.contributor.authorHong, DS
dc.contributor.authorConcin, N
dc.contributor.authorVergote, I
dc.contributor.authorde Bono, JS
dc.contributor.authorSlomovitz, BM
dc.contributor.authorDrew, Y
dc.contributor.authorArkenau, HT
dc.contributor.authorMachiels, JP
dc.contributor.authorSpicer, JF
dc.contributor.authorJones, R
dc.contributor.authorForster, MD
dc.contributor.authorCornez, N
dc.contributor.authorGennigens, C
dc.contributor.authorJohnson, ML
dc.contributor.authorThistlethwaite, Fiona C
dc.contributor.authorRangwala, RA
dc.contributor.authorGhatta, S
dc.contributor.authorWindfeld, K
dc.contributor.authorHarris, JR
dc.contributor.authorLassen, UN
dc.contributor.authorColeman, RL
dc.date.accessioned2020-06-15T12:57:38Z
dc.date.available2020-06-15T12:57:38Z
dc.date.issued2020en
dc.identifier.citationHong DS, Concin N, Vergote I, de Bono JS, Slomovitz BM, Drew Y, et al. Tisotumab Vedotin in Previously Treated Recurrent or Metastatic Cervical Cancer. Clin Cancer Res. 2020;26(6):1220-8.en
dc.identifier.pmid31796521en
dc.identifier.doi10.1158/1078-0432.ccr-19-2962en
dc.identifier.urihttp://hdl.handle.net/10541/622966
dc.language.isoenen
dc.relation.urlhttps://dx.doi.org/ 10.1158/1078-0432.ccr-19-2962en
dc.titleTisotumab vedotin in previously treated recurrent or metastatic cervical canceren
dc.typeArticleen
dc.contributor.departmentDepartment of Investigational Cancer Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texasen
dc.identifier.journalClinical Cancer Researchen
dc.description.noteen]


This item appears in the following Collection(s)

Show simple item record